Ovarian androgens but not estrogens correlate with the degree of systemic inflammation observed during controlled ovarian hyperstimulation

Gynecological Endocrinology

Volumn 21, Issue 3, 2005, Pages 170-173

  Orvieto, Raoul ^a,b,d   Fisch, Naama ^b   Yulzari Roll, Vered ^a,b   La Marca, Antonio ^c  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d BARZILAI MEDICAL CENTER   (Israel)

Author keywords

Androgens; C reactive protein; Controlled ovarian hyperstimulation; In vitro fertilization; Ovarian hyperstimulation syndrome

Indexed keywords

ANDROGEN; ANDROSTENEDIONE; C REACTIVE PROTEIN; CHORIONIC GONADOTROPIN; ESTRADIOL; ESTROGEN; GONADORELIN; PRASTERONE; SEX HORMONE; TESTOSTERONE;

ADULT; ANDROGEN BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL OBSERVATION; CORRELATION ANALYSIS; FEMALE; FERTILIZATION IN VITRO; HORMONE ACTION; HUMAN; INFLAMMATION; OVARY HYPERSTIMULATION; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE;

ADULT; ANDROSTENEDIONE; C-REACTIVE PROTEIN; DRUG ADMINISTRATION SCHEDULE; ESTROGENS; FEMALE; FERTILIZATION IN VITRO; GONADOTROPIN-RELEASING HORMONE; HUMANS; OVARY; OVULATION INDUCTION; PREGNANCY; PROSPECTIVE STUDIES; TESTOSTERONE;

EID: 27744434654     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590500279667     Document Type: Article

References (25)

1. Orvieto R, Voliovitch I, Fishman P, Ben-Rafael Z. Interleukin-2 and ovarian hyperstimulation syndrome-a pilot study. Hum Reprod 1995;10:24-27.
2. Orvieto R, Ben-Rafael Z. Ovarian hyperstimulation syndrome: a new insight into an old enigma. J Soc Gynecol Investig 1998;5:110-113.
3. Orvieto R. Controlled ovarian hyperstimulation-an inflammatory state. J Soc Gynecol Investig 2004;11:424-426.
4. Orvieto R, Chen R, Ashkenazi J, Ben-Haroush A, Bar J, Fisch B. C-reactive protein levels in patients undergoing controlled ovarian hyperstimulation for in vitro fertilization cycle. Hum Reprod 2004;19:357-359.
5. Sacks GP, Seyani L, Lavery S, Trew G. Maternal C-reactive protein levels are raised at 4 weeks' gestation. Hum Reprod 2004;19:1025-1030.
6. Kemmann E, Tavakoli F, Shelden RM, Jones JR. Induction of ovulation with menotropins in women with polycystic ovary syndrome. Am J Obstet Gynecol 1981;141:58-64.
7. Kelly CCJ, Lyall H, Petrie JR, Gould GW, Connel JMC, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2002;86:2453-2455.
8. Mohlig M, Spranger J, Osterhoff M, Ristow M, Pfeiffer AFH, Schul T, Schlosser HW, Brabant G, Schon C. The polycystic ovary syndrome per se is not associated with increased chronic inflammation. Eur J Endocrinol 2004;150:525-532.
9. Orvieto R, Schwartz A, Bar Hava I, Abir R, Ashkenazi J, LaMarca A, Ben-Rafael Z. Controlled ovarian hyperstimulation-a state of endothelial activation. Am J Reprod Immunol 2000;44:257-260.
10. Orvieto R, Ben Rafael Z, Schwartz A, Abir R, Fisch B, La-Marca A, Bar-Hava I. Soluble L-selectin levels during controlled ovarian hyperstimulation. Gynecol Endocrinol 2001;15:29-33.
11. Fanchin R, de Ziegler D, Castracane VD, Taieb J, Olivennes F, Frydman R. Physiopathology of premature progesterone elevation. Fertil Steril 1995;64:796-801.
12. Fanchin R, Righini C, Olivennes F, Taieb J, de Ziegler D, Frydman R. Premature plasma progesterone and androgen elevation are not prevented by adrenal suppression in in vitro fertilization. Fertil Steril 1997;67:115-119.
13. Martin KA, Hornstein MD, Taylor AE, Hall JE, Barbieri RL. Exogenous gonadotropin stimulation is associated with increases in serum androgen levels in in-vitro fertilization - embryo transfer cycles. Fertil Steril 1997;68:1011-1016.
14. Cedars MI, Surey E, Hamilton F, Lapolt P, Meldrum DR. Leuprolide acetate lowers circulating bioactive luteinizing hormone and testosterone concentrations during ovarian stimulation for oocyte retrieval. Fertil Steril 1990;53:627-631.
15. Tadmor OP, Kleinman Y, Barr I, Gal M, Brooks BA, Diamant YZ. Side effects of ovarian hyperstimulation: hormonal and lipid profile changes. Int J Fertil Menopausal Stud 1994;39:105-110.
16. Fanchin R, de Ziegler D, Taieb J, Olivennes F, Castracane D, Frydman R. Human chorionic gonadotropin administration does not increase plasma androgen levels in patients undergoing controlled ovarian hyperstimulation. Fertil Steril 2000;73:275-279.
17. Slater CC, Chang L, Stanczyk FZ, Paulson RJ. Altered balance between the 5α-reductase and aromatase pathways of androgen metabolism during controlled ovarian hyperstimulation with human menopausal gonadotropins. J Assist Reprod Genet 2001;18:527-533.
18. Casper RF, Erickson GF, Yen SS. Studies on the effect of gonadotropin-releasing hormone and its agonist on human luteal steroidogenesis in vitro. Fertil Steril 1984;42:39-43.
19. Castracane VD, Goldzieher JW. Plasma androgens during early pregnancy in the baboon (Papio cynocephalus). Fertil Steril 1983;39:553-559.
20. Almagor M, Hazav A, Yaffe H. The levels of C-reactive protein in women treated by IVF. Hum Reprod 2004;19:104-106.
21. Orvieto R. Prediction of ovarian hyperstimulation syndrome. Challenging the estradiol mythos. Hum Reprod 2003;18:665-667.
22. Liu PY, Death AK, Handelsman DJ. Androgens and cardiovascular disease. Endocr Rev 2003;24:313-340.
23. Molinari C, Battaglia A, Grossini E, Mary DA, Vassanelli C, Vacca G. The effect of testosterone on regional blood flow in prepubertal anaesthetized pigs. J Physiol 2002;543:365-372.
24. Worboys S, Kotsopoulos D, Teede H, McGrath B, Davis SR. Evidence that parenteral testosterone therapy may improve endothelium-dependent and -independent vasodilation in postmenopausal women already receiving estrogen. J Clin Endocrinol Metab 2001;86:158-161.
25. Szalai AJ, van Ginkel FW, Dalrymple SA, Murray R, McGhee JR, Volanakis JE. Testosterone and IL-6 requirements for human C-reactive protein gene expression in transgenic mice. J Immunol 1998;160:5294-5299.